Lyme disease testing presents a unique challenge in medicine: the test results can be misleading depending on when you get tested. This timing issue confuses many people who think one test is enough to know their status. Understanding why requires knowing how your body responds to the infection.
Learn About Paying Your FGUA Bill Online →
When a tick carrying the Borrelia burgdorferi bacteria infects you, your immune system doesn't immediately produce detectable antibodies. In the first few weeks after infection, standard antibody tests often come back negative even though you have the disease. This period—typically the first 3 to 4 weeks—is called the "serological window." During this window, blood tests that look for antibodies won't find them because your body hasn't had time to mount a full immune response yet.
The CDC estimates that roughly 30,000 cases of Lyme disease occur annually in the United States, though some surveillance experts believe the actual number may be significantly higher due to underdiagnosis and underreporting. The Northeast, upper Midwest, and Pacific Coast regions account for the majority of cases, though Lyme disease has been documented in all 50 states.
This timing problem means that a person with early-stage Lyme disease may test negative on a standard blood test, leading to delayed treatment or misdiagnosis. This is why physicians often rely on clinical symptoms and exposure history during the early phase rather than waiting for test confirmation. The disease's progression also matters: early localized Lyme disease (rash at the bite site) is different from early disseminated Lyme disease (infection spread to other parts of the body), which is different again from late Lyme disease (months or years after infection).
Practical takeaway: Timing of your test matters significantly. A negative test in the first few weeks doesn't rule out infection. If you suspect Lyme disease based on symptoms and tick exposure, discuss your clinical picture with a healthcare provider rather than relying solely on early test results.
The standard approach to Lyme disease testing in the United States follows a two-tier system recommended by the CDC. This isn't because one test is insufficient; it's because combining two different testing methods catches infections that one test alone might miss.
Free Guide to Pay by Plate Illinois Billing →
The first step uses an enzyme immunoassay (EIA) or immunofluorescence assay (IFA). These tests look for antibodies to Borrelia burgdorferi in your blood. Think of antibodies as your immune system's identification markers—when your body fights off the bacteria, it creates these markers so it can recognize the invader if it encounters it again. An EIA is faster and more standardized than IFA, which is why it's become the most common first-step test. If your EIA comes back negative, your testing stops here (though early infection may still be present if you're in that serological window). If it's positive or borderline, you move to step two.
The second step uses a Western blot test, which is more specific and detailed. While the EIA is like a general alarm system saying "something is detected," the Western blot is like examining the specific fingerprint of that something. The Western blot separates proteins from the bacteria and shows which ones your antibodies are reacting to. This prevents false positives from other infections (like some cases of syphilis or Epstein-Barr virus) that might trigger a positive EIA.
The two-tier approach has been in place since the 1990s and continues to be the gold standard. Studies show that when both tests are performed correctly, the system catches approximately 80-90% of cases in people with symptoms and confirmed exposure. The specificity is even higher, meaning false positives are uncommon when both steps are completed.
Some laboratories have introduced newer multiplex tests that can run simultaneously, combining elements of both steps. These may speed up results but still follow the same two-tier principle of initial screening followed by confirmatory testing.
Practical takeaway: If you get tested for Lyme disease, ask your healthcare provider or laboratory whether both steps of the two-tier protocol will be performed. A positive first test without a confirmatory second test is incomplete and can lead to misdiagnosis.
Not all Lyme disease tests work equally well at every stage of infection. The antibodies your body produces change over time, which means the same test can be negative one month and positive the next even without treatment—simply because your immune response has evolved.
Free Guide to Mold Removal Methods for Walls →
In early localized Lyme disease (the rash appears within 3 to 30 days of tick bite), serological tests (blood tests looking for antibodies) are frequently negative because antibodies haven't developed yet. During this stage, diagnosis relies heavily on clinical presentation: the characteristic "bull's-eye" rash called erythema migrans, plus exposure history. Only about 50-80% of people with Lyme disease develop the typical rash, so absence of a rash doesn't rule out infection. If a provider suspects early Lyme disease based on symptoms and geographic risk, treatment often begins without waiting for test confirmation.
In early disseminated Lyme disease (occurring weeks to months after infection, when the bacteria has spread), serological tests become more reliable. By this stage, your body has usually produced IgM antibodies (the first type of antibody your immune system makes in response to new infections). However, IgM antibody tests have higher false-positive rates and are less specific. This is why the two-tier system emphasizes using IgM results cautiously and preferring IgG antibodies (which develop later but are more specific) whenever possible.
In late Lyme disease (months to years after infection), serological testing becomes most reliable. By this point, IgG antibodies are well-developed and stable. If someone has had Lyme disease and was treated, they typically remain seropositive (testing positive) for years because antibodies persist. This creates a particular challenge: a positive test doesn't distinguish between current infection, recently treated infection, and infection from years past.
Some people pursue additional tests like C6 peptide tests, which measure antibodies to a specific protein fragment of the bacteria. These tests may help differentiate between exposure and active infection in certain situations, though they're not standard screening tools in most laboratories.
PCR (polymerase chain reaction) testing, which looks for bacterial DNA rather than antibodies, is sometimes discussed as an option. However, PCR is not recommended as a standard diagnostic test for Lyme disease because bacteria are rarely detectable in blood except very early in infection or in specialized samples like synovial fluid from joint fluid.
Practical takeaway: The best test depends on how long you've been sick. Early symptoms? Expect serological testing to be negative and rely on clinical judgment. Months into symptoms? Serological testing becomes more useful. When discussing testing with your provider, mention the timeline of your symptoms so the right test interpretation is applied.
A Lyme disease test result is not simply "positive" or "negative"—there's important nuance in what those results actually mean, and this is where confusion frequently occurs.
How to Delete Your Fitbit Account Guide →
When you receive an EIA or IFA result, it comes back as one of three categories: negative, borderline/equivocal, or positive. A negative result means no antibodies to Borrelia burgdorferi were detected. This can mean you don't have Lyme disease, or it can mean you have early-stage Lyme disease before antibodies developed. This is why a negative test should not rule out Lyme disease if symptoms and exposure history suggest it.
A borderline result is tricky. It means some antibodies were detected, but not quite at the threshold considered definitely positive. Borderline results often proceed to Western blot confirmation, and many turn out negative on the blot. Borderline results occasionally cause anxiety because they're not clearly reassuring, yet they're also not definitively positive.
A positive EIA result typically triggers Western blot testing. The Western blot examines specific protein bands and interprets them according to strict CDC criteria. For early Lyme disease (IgM Western blot), 2 out of 3 specific bands must be present to call it positive. For later Lyme disease (IgG Western blot), 5 out of 10 specific bands must be present. These numbers aren't
This guide is for general information only and is not medical, financial, legal, or other professional advice. For decisions specific to your situation, consult a qualified professional. See our Editorial Policy.